Oritavancin

Oritavancin

File:Oritavancin.svg
Identifiers
CAS Number	171099-57-3
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C86H97Cl3N10O26
Molar mass	1793.1 g/mol

WikiDoc Resources for Oritavancin
Articles
Most recent articles on Oritavancin Most cited articles on Oritavancin Review articles on Oritavancin Articles on Oritavancin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oritavancin Images of Oritavancin Photos of Oritavancin Podcasts & MP3s on Oritavancin Videos on Oritavancin
Evidence Based Medicine
Cochrane Collaboration on Oritavancin Bandolier on Oritavancin TRIP on Oritavancin
Clinical Trials
Ongoing Trials on Oritavancin at Clinical Trials.gov Trial results on Oritavancin Clinical Trials on Oritavancin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oritavancin NICE Guidance on Oritavancin NHS PRODIGY Guidance FDA on Oritavancin CDC on Oritavancin
Books
Books on Oritavancin
News
Oritavancin in the news Be alerted to news on Oritavancin News trends on Oritavancin
Commentary
Blogs on Oritavancin
Definitions
Definitions of Oritavancin
Patient Resources / Community
Patient resources on Oritavancin Discussion groups on Oritavancin Patient Handouts on Oritavancin Directions to Hospitals Treating Oritavancin Risk calculators and risk factors for Oritavancin
Healthcare Provider Resources
Symptoms of Oritavancin Causes & Risk Factors for Oritavancin Diagnostic studies for Oritavancin Treatment of Oritavancin
Continuing Medical Education (CME)
CME Programs on Oritavancin
International
Oritavancin en Espanol Oritavancin en Francais
Business
Oritavancin in the Marketplace Patents on Oritavancin
Experimental / Informatics
List of terms related to Oritavancin

Oritavancin (INN, also known as LY333328) is an investigational glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. It treats complicated skin and skin structure infections. This new drug will be tested for treatment of bacteraemia and nosocomial pneumonia. It demonstrates similar activity to vancomycin, but it has stronger activity against Staphylococcus and Enterococcus. The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely. The incidence of multi-drug resistant bacteria is increasing and explorations into additional treatment options are essential. The clinical efficacy of oritavancin has not yet been determined.

References

• Ward K, Mersfelder T, LaPlante K (2006). "Oritavancin--an investigational glycopeptide antibiotic". Expert Opin Investig Drugs. 15 (4): 417&ndash, 29. PMID 16548791.CS1 maint: Multiple names: authors list (link)

Template:GlycopeptideAntiBio

Template:WikiDoc Sources